Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Conditions
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent High Risk Myelodysplastic SyndromeRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Lymphoblastic LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Plasma Cell MyelomaHigh Risk Acute Myeloid LeukemiaLymphoproliferative Disorder
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT02861417
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02784054
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT02784015
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT02757885
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT02724904
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Allogeneic Stem Cell Transplantation for Children With CML
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 13
- Registration Number
- NCT02707393
- Locations
- 🇦🇹
Universitätsklinik für Kinder- und Jugendheilkunde, Graz, Austria
🇨🇿Hospital Motol, Department of Pediatric Hematology and Oncology, BMT Unit, Praha, Czechia
🇦🇹St. Anna Kinderspital, Wien, Austria
URMC Related Haplo-identical Donor BMT
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 74
- Registration Number
- NCT02660281
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02653196
- Locations
- 🇺🇸
The Children's Hospital at Montefiore, The Bronx, New York, United States
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT02605421
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.